Mindray (300760) Stock Price, Fundamentals & Analysis

What 300760 does

Mindray (300760) is a Shenzhen Stock Exchange stocks listing in the Healthcare sector, specifically the Medical Devices industry. Headquartered in Shenzhen, China, the company designs and manufactures a broad range of medical devices and solutions used in hospitals and clinics worldwide. Its product portfolio includes patient monitoring systems, ultrasound equipment, radiology devices, anesthesia machines, ventilators, electrocardiographs, endoscope camera systems, operating tables, surgical lights, infusion systems, and laboratory diagnostics equipment. The company also provides integrated IT solutions for clinical settings, such as M-connect IT, M-connect ER, M-connect ICU, M-connect OR, and M-connect CCU solutions. Founded in 1991, Mindray serves both the Chinese and international markets.

Key numbers explained

• 153.86 CNY is the latest trading price of Mindray (300760).
• The trailing P/E ratio of 23.7 shows how much investors pay per unit of past earnings; a lower figure can suggest a stock is cheaper relative to its earnings, though comparisons within the same sector matter.
• The forward P/E ratio of 19.4 uses expected future earnings, giving a sense of valuation based on what analysts anticipate.
• 6.49 CNY is the trailing 12-month earnings per share, representing the portion of profit allocated to each share.
• The dividend yield of 2.76% indicates the annual dividend income as a percentage of the current share price.
• The ex-dividend date of 8 sept. 2026 is the cutoff: buyers on or after this date do not receive the upcoming dividend.
• 65% of earnings are paid out as dividends, showing the company returns a majority of its profit to shareholders.
• The beta of 0.19 suggests the stock tends to be much less volatile than the overall market.
• The 52-week price range of 130,66 – 248,98 shows the lowest and highest traded prices over the past year.
• 34.29 mld. CNY is the trailing 12-month revenue, and 10.5% year-over-year revenue growth shows how fast top-line sales are expanding.
• A profit margin of 22.9% and operating margin of 33.2% reflect how much of each revenue yuan remains as profit after costs and operating expenses.
• The return on equity of 18.5% measures how effectively the company generates profit from shareholders' capital.
• The debt-to-equity ratio of 0,7 (or 0.7) indicates the company uses less debt than equity to finance its operations.
• Price-to-book of 4.6 compares the market price to the book value of the company's assets.

What to watch

Investors tracking Mindray (300760) may monitor factors common to the Medical Devices sector and the broader Healthcare space. Revenue growth, profit margins, and product innovation cycles can influence the company's trajectory. Regulatory changes in medical device approvals, both in China and internationally, may affect sales timelines. The company's dividend policy and payout ratio are relevant for income-focused investors. As a component of the CSI 300 index, Mindray's performance can be influenced by broader Chinese large-cap trends. Peer companies such as China Resources Sanjiu Medical & Pharmaceutical (000999), Zhejiang NHU (002001), Hangzhou Tigermed Consulting (300347), Aier Eye Hospital (300015), Chang Chun High and New Technology Industry (Group) (000661), Walvax Biotechnology (300142), and Shijiazhuang Yiling Pharmaceutical (002603) operate in related healthcare and medical fields and may provide context for sector comparisons.